{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"CFMZQSDQCNKGII-UHFFFAOYSA-N","prefName":"CUMYL-CBMINACA","symbol":"CUMYL-CBMINACA","iupacName":"1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide","aliases":["Cumyl-CBMINACA","3DAF3CP9N5","SGT277"],"cas":null,"pubchemCid":"155884799","chebiId":null,"smiles":"CC(C)(C1=CC=CC=C1)NC(=O)C2=NN(C3=CC=CC=C32)CC4CCC4","molecularFormula":"C22H25N3O","molecularWeight":347.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/155884799"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: the molecule exists in no living organism and comes exclusively from organic synthesis of the indazole-3-carboxamide class, by forming an amide bond on carbon 3 of the indazole nucleus. Manufacture is described here by chemical class only.","originNote":"A fully synthetic molecule, absent from cannabis and from any living organism. According to Haschimi et al. (2021), it belongs to a subclass whose products were distributed through online shops before disappearing from the market. Pulver et al. (2023) report that this cyclobutylmethyl fragment made it possible to circumvent German legislation, and that exploratory synthetic cannabinoids appeared between 2019 and 2021.","discovered":""},"pharmacology":{"summaryFr":"CUMYL-CBMINACA is a synthetic indazole-3-carboxamide combining a cyclobutylmethyl fragment on nitrogen 1 of the indazole nucleus with a cumyl head. Haschimi et al. (2021) measure on the human CB1 receptor an affinity of 1.32 nM, higher than that of its indole analogue CUMYL-CBMICA (Ki of 29.3 nM), and an EC50 of 55.4 nM in GTPγS activation. Pulver et al. (2023) classify it among the full CB1 agonists, in comparison with delta-9-THC and CP-55,940. The abstracts of the two cited papers describe no clinical study and no data on the CB2 receptor, and no safe amount is defined. Classified as a narcotic in France under the generic clause for 3-carboxamide indazole derivatives, it is not named on the ANSM list.","receptorSummaryFr":"CB1 agonist at the human CB1 receptor. Haschimi et al. (2021) measure on cell membranes expressing hCB1 a binding affinity Ki of 1.32 nM, an EC50 of 55.4 nM in GTPγS activation and a maximal efficacy (Emax) of 207%, a higher affinity and potency than those of CUMYL-CBMICA (Ki of 29.3 nM, EC50 of 497 nM). Pulver et al. (2023) classify it among the full CB1 agonists, in comparison with delta-9-THC and CP-55,940. The abstracts of the two cited papers report no data on the CB2 receptor, nor on TRPV1, GPR55 or PPARγ.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":96,"reported":"Ki 1,32 nM (hCB1, Haschimi et coll., 2021) ; EC50 de 55,4 nM et Emax de 207 % en activation GTPγS (Haschimi et coll., 2021)","confidence":"medium"}],"references":[{"label":"Haschimi et coll., nouveaux cannabinoïdes de synthèse à chaîne cyclobutylméthyle, métabolisme phase I humain et affinité CB1 du CUMYL-CBMICA et du CUMYL-CBMINACA, Drug Testing and Analysis 2021","pmid":"33788409","doi":"10.1002/dta.3038","url":"https://pubmed.ncbi.nlm.nih.gov/33788409/"},{"label":"Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des agonistes cyclobutylméthyle et norbornylméthyle, Drug Testing and Analysis 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (définition « dérivés du 3-carboxamide indazole »)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-CBMINACA, CID 155884799","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/155884799"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":8},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":3},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":8},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":10},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":10}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure targeting this molecule was identified in the sources consulted. It is also absent from the 2026 Green List of the International Narcotics Control Board, which reproduces the schedules of the 1971 Convention on Psychotropic Substances. According to Pulver et al. (2023), Germany scheduled in 2020, through an amendment to its law on new psychoactive substances, all synthetic cannabinoids with a cyclobutylmethyl side chain. Its control therefore rests on national legislation.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"The molecule is not named in the consolidated list of substances classified as narcotics published by ANSM (update of 16 February 2026). It does, however, meet each condition of the generic definition “derivatives of 3-carboxamide indazole” in that list: a cycloalkylmethyl substituent on nitrogen 1 of the indazole nucleus (here cyclobutylmethyl), an indazole nucleus that may or may not be substituted (here unsubstituted), and a carboxamide nitrogen bearing a cumyl substituent. The list moreover cites CUMYL-PINACA, which carries the same cumyl head, as an example of this family. It therefore falls under the narcotics regime.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Haschimi et coll., nouveaux cannabinoïdes de synthèse à chaîne cyclobutylméthyle, métabolisme phase I humain et affinité CB1 du CUMYL-CBMICA et du CUMYL-CBMINACA, Drug Testing and Analysis 2021","pmid":"33788409","doi":"10.1002/dta.3038","url":"https://pubmed.ncbi.nlm.nih.gov/33788409/"},{"label":"Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des agonistes cyclobutylméthyle et norbornylméthyle, Drug Testing and Analysis 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (définition « dérivés du 3-carboxamide indazole »)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-CBMINACA, CID 155884799","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/155884799"}],"meta":{"slug":"cumyl-cbminaca","url":"https://en.phytogrammes.com/wiki/cumyl-cbminaca","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}